Personalized immunotherapy response studied in body-on-a-chip cancer models

Wake Forest researchers and clinicians are using patient-specific tumor ‘organoid’ models as a preclinical companion platform to better evaluate immunotherapy treatment for appendiceal cancer, one of the rarest cancers affecting only 1 in 100,000 people. Immunotherapies, also known as biologic therapies, activate the body’s own immune system to control, and eliminate cancer. Appendiceal cancer is historically resistant to systemic chemotherapy, […]

Read more

SFRP2 and PD-1 immunotherapy combination halts osteosarcoma metastasis in model

In a cancer that has not seen new targeted therapies for over 20 years, MUSC Hollings Cancer Center researcher and oncologist Nancy Klauber-DeMore, M.D., is pioneering new discoveries. Using a combination of personal passion and expertise, Klauber-DeMore shifted her knowledge of the pro-angiogenic protein SFRP2 in breast cancer to address the lack of treatment options for patients with aggressive metastatic […]

Read more

Study reveals cancer immunotherapy patients at most risk of life-threatening side effects

Many patients with cancer receive immune checkpoint inhibitors that strengthen their immune response against tumor cells. While the medications can be life-saving, they can also cause potentially life-threatening side effects in internal organs. This double-edged sword makes it challenging for clinicians to decide who should be considered candidates for treatment. A new analysis led by researchers at Massachusetts General Hospital […]

Read more

A collaborative effort to evaluate treatment of liver and pancreatic tumors

HOUSTON, DENVER and CHICAGO ? The University of Texas MD Anderson Cancer Center and TriSalus Life Sciences today announced a strategic research collaboration to evaluate the treatment of tumors of the pancreas and liver by integrating interventional delivery of SD-101, an investigational toll-like receptor 9 (TLR9) agonist, in combination with checkpoint inhibition immunotherapy. Under the agreement, MD Anderson and TriSalus […]

Read more

Newly identified biomarker could predict response to immune checkpoint inhibitors

A team of Roswell Park Comprehensive Cancer Center researchers has identified a new biomarker that could predict response to immune checkpoint inhibitors (ICI) shortly after patients with non-small cell lung cancer (NSCLC) initiate therapy. This discovery, published today in the journal Nature Communications, is not only an important step forward in lung cancer treatment, but also has implications for other […]

Read more

uses of bupropion

Order Medicines & Health Products from Online Pharmacy for Skin, Hair, Heart and all Personal Daily Health. Baby, Men, Women & Elderly care Products Online. Buy prescription medicines, OTC products & household needs.

Read more

New analysis method for predicting the risks and effects of immunotherapy

In a new study, researchers at Uppsala University have been able to show differences in how rituximab, a monoclonal antibody drug, interacts with the blood of healthy individuals compared to patients with chronic lymphatic leukemia. This has awakened hopes that this analysis method could pave the way for important breakthroughs in immunotherapy research and treatment. Immunotherapy—using the body’s own immune […]

Read more

Fighting breast cancer with nanotech, immunotherapy

A team of scientists led by a researcher at the Case Western Reserve University School of Medicine is making strides to fight deadly metastatic breast cancer by combining nanotechnology with immunotherapy. Efstathios “Stathis” Karathanasis, an associate professor of biomedical engineering, is directing the novel technique—sending nanoparticles into the body to wake up “cold” tumors so they can be located and […]

Read more

‘Deep dive’ into biology of kidney tumors identifies markers of response to immunotherapy

Treatments for kidney cancer have improved considerably over the past few decades. In 1988, when Memorial Sloan Kettering oncologist Robert Motzer started researching the disease, the average survival was less than one year. There were no approved therapies at the time besides surgery. By 2005, with the development of targeted drugs such as sunitinib (Sutent), survival nearly tripled. Today, with […]

Read more

A machine learning-based algorithm to predict which cancer patients benefit from immunotherapy

Scientists at the Institute for Research in Biomedicine (IRB Barcelona), in collaboration with the Centre for Genomic Regulation (CRG) and Radboud University, have developed an algorithm that can predict which cancer patients are more likely to benefit from immunotherapy. Mutations in our DNA can disrupt protein synthesis, sometimes causing truncated proteins which don’t work as intended. Known as nonsense mutations, […]

Read more
1 2